Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jan 19 2022

Full Issue

Patient Groups Try Calling Medicare Officials Villains Over Aduhelm Ruling

Politico covers aggressive pushback from drugmakers and patient advocacy groups over the recent decision to strongly limit Medicare coverage of Alzheimer's drug Aduhelm. Meanwhile, Axios says six big health insurers dominate the fast-growing Medicare Advantage market.

Politico: ‘Not A Tolerable Situation’: Patient Groups Take Aim At CMS Over Alzheimer’s Coverage Decision 

Drugmakers and patient advocacy groups are waging a campaign to cast Medicare officials as villains after the program limited coverage of a pricey new Alzheimer’s drug and demanded tougher criteria than the FDA to prove it works. Their goal is to strong arm the Centers for Medicare and Medicaid Services into covering Aduhelm, the $28,200-per-year drug, for far more people. (Foley and Wilson, 1/17)

And more about the insurance industry —

Axios: UnitedHealth, Other Big Medicare Advantage Insurers Dominate 2022 

Six health insurers control roughly three-quarters of the fast-growing Medicare Advantage market, according to an Axios analysis of federal data. Medicare Advantage enrollment hasn't slowed down in 2022, even though dismal projections from Humana and Cigna freaked out Wall Street earlier this month, and concentration at the top remains high. (Herman, 1/19)

Axios: Insurers May Face Scrutiny Over Birth Control Coverage 

Health insurers could face increased scrutiny and potential enforcement actions regarding their coverage of birth control, following recent guidance from the Biden administration. The ACA requires birth control coverage with no cost-sharing, but some advocates and Democrats in Congress have said insurers are running afoul of the law with restrictions. (Reed, 1/18)

KHN: HHS Proposal For Marketplace Plans Carries A Hefty Dose Of Consumer Caution

Some insurance brokers are enrolling people into Affordable Care Act health plans without their consent, perhaps for the commissions, a move that could put consumers in danger of owing back the subsidies connected with the coverage. The damage could be hundreds or even thousands of dollars. A consumer’s first hint that something is wrong is a big one: a letter from the IRS or a delay in their tax refund. (Appleby, 1/19)

In other health care industry updates —

Crain's Detroit Business: Bottleneck In Acute Care Pipeline Leaves Patients With Nowhere To Go

Last week, case managers at Sparrow Specialty Hospital in Lansing finalized the transfer of a patient. She had contracted COVID-19 nearly three months earlier and required a tracheotomy, a common practice in critically-ill patients with a prolonged need for a ventilator. She was ready to leave Sparrow Specialty's care many weeks earlier but staffing, transportation and beds are in short supply. Sparrow Specialty's case managers sent 60 transfer requests for the patient before a room opened up at Mary Free Bed only one floor above. (Walsh, 1/18)

Modern Healthcare: FTC, DOJ Ask For Public Input In Antitrust 'Overhaul'

The FTC has asked several of the major insurers for data on hospital acquisition of physicians as the healthcare sector continues to vertically consolidate. It is also reworking its vertical merger guidelines, which are expected to bolster an enforcement area where regulators have historically had limited success. About 90% of acute-care markets in metro areas are highly concentrated, lawmakers have said, noting that many hospitals amass market power through small transactions that skirt regulatory review. Most hospital mergers raise prices and stunt quality, research shows. (Kacik, 1/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF